21 Dec 2007 - Ablynx announced that its TNF-alpha partnership with Wyeth Pharmaceuticals has been extended for another year. Wyeth and Ablynx are collaborating to discover and develop novel Nanobody®-based therapeutics against TNF-alpha. Wyeth has exclusive rights to develop and commercialise the anti-TNF-alpha Nanobodies® developed under the collaboration.
As part of the collaboration Ablynx receives research funding and would be entitled to future milestone payments and royalties upon commercialisation.
Dr. Edwin Moses, CEO and Chairman of Ablynx, commented: "We are very pleased with the progress of our partnership with Wyeth, which has world class capabilities in the development and commercialisation of biologics. We look forward to continuing our collaboration for another year. This is an important partnership for Ablynx and we are delighted to continue our joint efforts to advance the TNF-alpha Nanobody®-based programme to the next stage."
 |
www.bionity.com/news/e/76031 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/76031 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |